Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors.

Inflammatory bowel diseases - 1 Apr 2007

Hlavaty Tibor, Ferrante Marc, Henckaerts Liesbet, Pierik Marie, Rutgeerts Paul, Vermeire Severine

Abstract excerpt

BACKGROUND: Infliximab (IFX) is an effective therapy for refractory luminal and fistulizing Crohn's disease (CD). Predictors of response could improve selection of patients with a higher probability of favorable outcomes and could improve the safety profile. We aimed to develop a predictive model for the response to infliximab in CD. METHODS: Genetic and clinical data collected in a previous pharmacogenetic study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Inflammatory Agents
Share to Antibodies, Monoclonal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Apoptosis

Share to Crohn Disease

Share to Decision Trees

Share to Forecasting

Share to Infliximab

Share to Pharmacogenetics

Source

Identifiers

PMID: 17206723
DOI: 10.1002/ibd.20024

Genes

CRP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors.PMID 17206723Read ↗

Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.Semantic proximity Read ↗

Response to Infliximab in Crohn's Disease: Genetic Analysis Supporting Expression Profile.Semantic proximity Read ↗

Development and Validation of an Interleukin-6 Nomogram to Predict Primary Non-response to Infliximab in Crohn’s Disease Patients: From Bedside to Bioinformatics.Semantic proximity Read ↗

Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitisSemantic proximity Read ↗

[Tumor necrosis factor-related apoptosis-inducing ligand gene polymorphism and its plasma phenotype in relation to Crohn's disease].Semantic proximity Read ↗

To evaluate the predictive effect of vitamin D on clinical outcomes of infliximab treated Crohn’s disease patients in western ChinaSemantic proximity Read ↗

Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience.Semantic proximity Read ↗

Bayesian Machine Learning Techniques for revealing complex interactions among genetic and clinical factors in association with extra-intestinal Manifestations in IBD patients.Semantic proximity Read ↗

Thiopurine effectiveness in patients with Crohn's disease: a study of genetic and clinical predictive factors.Semantic proximity Read ↗

Pharmacokinetic model selection for infliximab based on inflammatory bowel disease phenotype and severity: Toward model-informed precision dosing.Semantic proximity Read ↗

Investigation of the prognostic value of TNF-alpha gene polymorphism among patients treated with infliximab, and the effects of infliximab therapy on TNF-alpha production and apoptosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.